TipRanks
Ascendis Pharma (ASND)
NASDAQ:ASND
US Market
ASND
Ascendis Pharma
RESEARCH TOOLSreports
Want to see ASND full AI Analyst Report?

Ascendis Pharma (ASND) Stock News & Sentiment

774 Followers
Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target
Premium
Ratings
Ascendis Pharma: Strong Commercial Momentum Across Yorvipath, Yuviwel, and Skytrofa Drives Buy Rating with Unchanged $304 Price Target
12h ago
ASND
Ascendis Pharma Closes Warrant Exercise Window, Lifts Share Capital on September 29, 2026
Premium
Company Announcements
Ascendis Pharma Closes Warrant Exercise Window, Lifts Share Capital on September 29, 2026
10d ago
6K
ASND
Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets
Premium
Ratings
Ascendis Pharma: Buy Rating Reaffirmed as Analyst Maintains $344 12‑Month Price Target Amid Strategic Upside From TransCon Assets
24d ago
ASND
Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target
Premium
Ratings
Ascendis Pharma: Buy Rating Reaffirmed as Durable Franchise, New Launches, and $400M Buyback Support Unchanged $319 Price Target
24d ago
ASND
Ascendis Pharma Unveils $400 Million Share Repurchase Program
Premium
Company Announcements
Ascendis Pharma Unveils $400 Million Share Repurchase Program
25d ago
6K
ASND
Ascendis Pharma Regains Full Rights to TransCon Metabolic and Cardiovascular Programs After Novo Nordisk Split
Premium
Company Announcements
Ascendis Pharma Regains Full Rights to TransCon Metabolic and Cardiovascular Programs After Novo Nordisk Split
25d ago
6K
ASND
Ascendis Pharma: Buy Rating Reiterated as YUVIWEL Infant Data Strengthen CNP Therapy Case; Price Target Maintained at $344
Premium
Ratings
Ascendis Pharma: Buy Rating Reiterated as YUVIWEL Infant Data Strengthen CNP Therapy Case; Price Target Maintained at $344
29d ago
ASND
More ASND News >

ASND News on the Web

RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)
TipRanks News
Bullish
RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP)
GuruFocus News
Neutral
Ascendis Pharma Closes Warrant Exercise Window, Lifts Share Capital on September 29, 2026
TipRanks News
Neutral
Ascendis Pharma Sinks After Novo Nordisk Exit Shock
TipRanks News
Neutral
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
Insider Monkey
Neutral
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
Insider Monkey
Neutral
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
ASND
Sector Average
Media Buzz
This Week4 articles
Weekly Average10.25 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ASND’s Media Buzz Sentiment?
4 articles about ASND were published this week. In an average week, 10.25 articles are published.
    What is ASND’s weekly average amount of articles?
    In an average week, 10.25 articles about ASND are published.
      What is ASND’s News Sentiment?
      100% of articles about ASND were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        AMGNAmgen
        MCKMcKesson
        ONCBeOne Medicines
        NVSNovartis
        NTRANatera
        Showing the stocks with the most bullish news sentiment over the past week